HIMS / Hims & Hers Health, Inc. - SEC-arkivering, Årsberetning, Fuldmagtserklæring

Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World’s Largest Consumer Health Platform The acquisition extends the company's leadership position across Australia, Canada, Germany, Japan, and the United Kingdom, with t

Hims & Hers Completes Acquisition of Eucalyptus, Advancing its Position as the World’s Largest Consumer Health Platform The acquisition extends the company's leadership position across Australia, Canada, Germany, Japan, and the United Kingdom, with the scale to redefine healthcare for hundreds of millions of people SAN FRANCISCO, June 2, 2026 – Hims & Hers Health, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2026 HIMS & HERS HEALTH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2026 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission F

AMENDMENT NO. 3 TO REVOLVING CREDIT AND GUARANTY AGREEMENT

Execution Version AMENDMENT NO. 3 TO REVOLVING CREDIT AND GUARANTY AGREEMENT THIS AMENDMENT NO. 3 (this “Amendment”), dated as of May 29, 2026, by and among HIMS & HERS HEALTH, INC., a Delaware corporation (the “Borrower”), and each existing Lender party hereto, which constitute at least the Required Lenders under the Existing Credit Agreement (as defined below) (such Lenders party hereto, collect

[Signature Page to Base Capped Call Confirmation]

EX-10.1 Exhibit 10.1 [Dealer Name and Address] May 18, 2026        To: Hims & Hers Health, Inc. 2269 Chestnut Street #523 San Francisco, CA 94123 Attention: Legal Department Re: Base Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [Dealer Name] (“Dealer”) and Hims & Hers He

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2026 HIMS & HERS HEALTH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2026 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission F

HIMS & HERS HEALTH, INC. U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee Dated as of May 21, 2026 0.00% Convertible Senior Notes due 2032

EX-4.1 Exhibit 4.1 Execution Version HIMS & HERS HEALTH, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of May 21, 2026 0.00% Convertible Senior Notes due 2032 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 13 Section 1.03. Rules of Construction 14 Article 2. The Notes 15 Secti

Conversion Settlement Date/Repayment Date

EX-10.2 Exhibit 10.2 [Dealer Name and Address] May 19, 2026 To: Hims & Hers Health, Inc. 2269 Chestnut Street #523 San Francisco, CA 94123 Attention: Legal Department Re: Additional Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [Dealer Name] (“Dealer”) and Hims & Hers Hea

Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment

EX-99.2 Exhibit 99.2 Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment Proceeds intended to be used to preserve financial flexibility as Hims & Hers executes on its international expansion strategy, including the proposed acquisition of Eucalyptus, invests in technology and operatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2026 HIMS & HERS HEALTH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2026 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission F

Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment

EX-99.1 Exhibit 99.1 Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment Proceeds intended to be used to preserve financial flexibility as Hims & Hers executes on its international expansion strategy, including the proposed acquisition of Eucalyptus, invests in technology and operational infra

AMENDMENT NO. 2 TO REVOLVING CREDIT AND GUARANTY AGREEMENT

Execution Version AMENDMENT NO. 2 TO REVOLVING CREDIT AND GUARANTY AGREEMENT THIS AMENDMENT NO. 2 (this “Amendment”), dated as of May 7, 2026, by and among HIMS & HERS HEALTH, INC., a Delaware corporation (the “Borrower”), and each existing Lender party hereto, which constitute at least the Required Lenders under the Existing Credit Agreement (as defined below) (such Lenders party hereto, collecti

Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results Revenue of approximately $608 million, up 4% year-over-year in Q1 2026 Subscribers grew to nearly 2.6 million, up 9% year-over-year in Q1 2026 Raises full year 2026 revenue guidanc

Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results Revenue of approximately $608 million, up 4% year-over-year in Q1 2026 Subscribers grew to nearly 2.6 million, up 9% year-over-year in Q1 2026 Raises full year 2026 revenue guidance1 to a range of $2.8 billion to $3.0 billion and updates Adjusted EBITDA guidance to a range of $275 million to $350 million SAN FRANCISCO, May 11, 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2026 HIMS & HERS HEALTH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2026 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  ☐ D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De

ARS

+$*
)**) )+(*)
$
.$
%##))%$ -3E:;@9FA@
 
  %(#
! 



))0'
- +*-/
+0-.0)/
/*
. /$*)

*-
<
*!
/#
. 0-$ /$ .
3#)"
/
*!
 AD
F:7
;E53>
/73D
@676
757?47D
 
  *- 




/-).$/$*)
- +*-/
+0-.0)/
/*
. /$*)

*-
<
*!
/#
. 0-$/$ .
3#)"
/
*!

!GJ
L@=
LJ9FKALAGF
H=JAG<
>JGE
























LG
888888888888 #)

()

Hims & Hers announces strategic shift for US weight loss business Starting with a new collaboration with Novo Nordisk, the company announced plans to align its US and global strategies with a focus on an increasing variety of FDA-approved GLP-1s

Hims & Hers announces strategic shift for US weight loss business Starting with a new collaboration with Novo Nordisk, the company announced plans to align its US and global strategies with a focus on an increasing variety of FDA-approved GLP-1s SAN FRANCISCO, March 9, 2026 – Hims & Hers Health, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2026 HIMS & HERS HEALTH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2026 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 Hims & Hers Health, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Class A Common Stock, par value $0.0001 per share Other 11,362,276 $ 15.47 $ 175,774,409.72 0.0001381 $ 24,2

As filed with the Securities and Exchange Commission on February 24, 2026

As filed with the Securities and Exchange Commission on February 24, 2026 Registration No.

November 25, 2022

Hims, Inc. 2269 Chestnut #523 San Francisco, CA 94123 November 25, 2022 Patrick Carroll Re: Offer Letter and Employment Terms Dear Patrick, 1.Position. HIMS, INC., and/or any of its past, present, and future parent companies, subsidiaries, predecessors, successors, affiliates, and acquisitions (the “Company”) is pleased to offer you the position of Chief Medical Officer, on the following terms. Pe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTI

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name of r

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results Revenue of approximately $2.35 billion, up 59% year-over-year in 2025 Net income of $128 million; Adjusted EBITDA of $318 million in 2025 Subscribers grew to over 2.5 million, up 13% year-over-year in 2025 Provides Q1 and full year 2026 guidance1, with full year 2026 revenue in the range of $2.7 billion to $2.9 bi

Hims, Inc.

Hims, Inc. 2269 Chestnut St. #523 San Francisco, CA 94123 April 30, 2025 Mohamed Elshenawy Re: Offer Letter and Employment Terms Dear Mohamed, 1.Position. HIMS, INC., and/or any of its past, present, and future parent companies, subsidiaries, predecessors, successors, affiliates, and acquisitions (the “Company”) is pleased to offer you the position of Chief Technology Officer, on the following ter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2026 HIMS & HERS HEA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2026 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

SUBSIDIARIES OF HIMS & HERS HEALTH, INC.

Exhibit 21 SUBSIDIARIES OF HIMS & HERS HEALTH, INC. DOMESTIC COMPANIES Name Jurisdiction of Incorporation Hims, Inc. Delaware H&H Healthcare Management, Inc. Delaware YourBio Health, Inc. Delaware H&H Pharmacy Management, Inc. Delaware H&H Pharmacy Holdings, Inc. Delaware H&H Peptides, Inc. Delaware H&H Labs, LLC Delaware Seaview Enterprises LLC (dba MedisourceRx) California Apostrophe Pharmacy LL

March 15, 2021

Hims, Inc. 2269 Chestnut #523 San Francisco, CA 94123 March 15, 2021 Michael Chi Re: Offer Letter and Employment Terms Dear Michael: 1.Position. HIMS, INC., (the “Company”) is pleased to offer you the position of SVP Growth, on the following terms. You will work remote out of New York, on a mutually agreed upon date or on or about April 19, 2021 (“Start Date”). Of course, the Company may change yo

hhtorm iHSA100 milf595100 m Feeling good in your body & mind transforms how you show up in life. That’s why we’re on a mission to help the world feel great through the power of better health. 2 Hims & Hers Q4 2025 *This is a non-GAAP financial measur

finalq42025shareholderle hhtorm iHSA100 milf595100 m Feeling good in your body & mind transforms how you show up in life.

April 20, 2025 Nader Kabbani

Hims, Inc. 2269 Chestnut St. #523 San Francisco, CA 94123 April 20, 2025 Nader Kabbani Re: Offer Letter and Employment Terms Dear Nader, 1.Position. HIMS, INC., and/or any of its past, present, and future parent companies, subsidiaries, predecessors, successors, affiliates, and acquisitions (the “Company”) is pleased to offer you the position of Chief Operating Officer, on the following terms. Per

Hims, Inc. January 5, 2021

Hims, Inc. January 5, 2021 Soleil Boughton Dear Soleil: Hims, Inc. (the “Company”) is pleased to offer you continuing employment on the following terms, effective as of the closing of the transactions contemplated by that certain Agreement and Plan of Merger by and among Oaktree Acquisition Corp., Rx Merger Sub, Inc. and the Company. 1.Position. Your title will be Chief Legal Officer of Hims & Her

Re: Offer Letter and Employment Terms

Hims, Inc. 2269 Chestnut St. #523 San Francisco, CA 94123 October 17, 2025 Deborah M. Autor Re: Offer Letter and Employment Terms Dear Deborah: 1.Position. HIMS, INC., and/or any of its past, present, and future parent companies, subsidiaries, predecessors, successors, affiliates, and acquisitions (the “Company”) is pleased to offer you the position of Chief Policy Officer, on the following terms.

Transition and Advisor Agreement

Transition and Advisor Agreement Effective November 2, 2025 (the “Effective Date”), Nader Kabbani (“Advisor”) and Hims, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026 HIMS & HERS HEA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

CERTAIN INFORMATION CONTAINED IN THIS SECURITIES SALE DEED HAS, PURSUANT TO ITEM 601(B)(2) OF REGULATION S-K, BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE SUCH INFORMATION IS BOTH NOT MATERIAL AND IS TH

Exhibit 2.1 CERTAIN INFORMATION CONTAINED IN THIS SECURITIES SALE DEED HAS, PURSUANT TO ITEM 601(B)(2) OF REGULATION S-K, BEEN OMITTED BY MEANS OF REDACTING A PORTION OF THE TEXT AND REPLACING IT WITH [***] BECAUSE SUCH INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXECUTION VERSION Securities Sale Deed Project Eagle Each par

Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan a

Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 HIMS & HERS HEA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2025 HIMS & HERS HEAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commissi

Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results Revenue of nearly $600 million, up 49% year-over-year in Q3 2025 Net income of nearly $16 million; Adjusted EBITDA of over $78 million in Q3 2025 Subscribers grew to almost 2.5 mil

Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results Revenue of nearly $600 million, up 49% year-over-year in Q3 2025 Net income of nearly $16 million; Adjusted EBITDA of over $78 million in Q3 2025 Subscribers grew to almost 2.5 million, up 21% year-over-year in Q3 2025 Narrows full year 2025 revenue guidance to $2.335 billion to $2.355 billion and Adjusted EBITDA guidance to $30

Transition and Advisory Agreement Effective August 30, 2025 (the “Effective Date”), Melissa Baird (“Advisor”) and Hims, Inc. (“Company”) agree as follows: 1. Transition. In connection with Advisor’s retirement as an officer of the Company, effective

hims-20250930x10qxex103 Transition and Advisory Agreement Effective August 30, 2025 (the “Effective Date”), Melissa Baird (“Advisor”) and Hims, Inc.

Feeling good in your body & mind transforms how you show up in life. That’s why we’re on a mission to help the world feel great through the power of better health. 2 Hims & Hers Q3 2025 Key Financial Highlights Q3 2025 Q3 2024 Growth Revenue $599M $4

finalq32025shareholderle Feeling good in your body & mind transforms how you show up in life.

144

144 0001965903 XXXXXXXX LIVE 0001773751 Hims & Hers Health, Inc. 001-38986 2269 CHESTNUT ST #523 SAN FRANCISCO CA 94123 415-851-0195 Chi Michael Officer Class A Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 900 52425.00 217641958 10/10/2025 NYSE Class A 10/10/2025 Option Granted - 08/10/2022 Issuer N 900 10/10/2025 Cash N Michael Y. Chi 2269 Chestnut Street #523 San Francisc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2025 HIMS & HERS HE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commis

144

144 0001965903 XXXXXXXX LIVE 0001773751 Hims & Hers Health, Inc. 001-38986 2269 CHESTNUT ST #523 SAN FRANCISCO CA 94123 415-851-0195 Chi Michael Officer Class A Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 250 14000.00 217641958 10/01/2025 NYSE Class A 10/01/2025 Options Granted - 03/01/2023 Issuer N 250 10/01/2025 Cash N Michael Y. Chi 2269 Chestnut Street #523 San Francis

144/A

144/A 0001958244-25-004349 0001907056 XXXXXXXX LIVE 0001773751 Hims & Hers Health, Inc.

144

144 0001837817 XXXXXXXX LIVE 0001773751 Hims & Hers Health, Inc. 001-38986 2269 CHESTNUT ST #523 SAN FRANCISCO CA 94123 415-851-0195 Boughton Soleil Officer Class A Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 2637 155029.23 217641958 09/29/2025 NYSE Class A 09/15/2025 Restricted Stock Vesting Issuer N 2637 09/15/2025 Compensation N Soleil Boughton 2269 Chestnut Street #523

144

144 0001965903 XXXXXXXX LIVE 0001773751 Hims & Hers Health, Inc. 001-38986 2269 CHESTNUT ST #523 SAN FRANCISCO CA 94123 415-851-0195 Chi Michael Officer Class A Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 2100 118692.00 217641958 09/24/2025 NYSE Class A 09/24/2025 Option Granted - 02/24/2022 Issuer N 2100 09/24/2025 Compensation N Michael Y. Chi 2269 Chestnut Street #523 S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2025 HIMS & HERS HE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commis

144

144 0001907056 XXXXXXXX LIVE 0001773751 Hims & Hers Health, Inc. 001-38986 2269 Chestnut Street Suite 523 San Francisco CA 94123 1-415-851-0195 Oluyemi Okupe Officer Common Goldman Sachs & Co. LLC 200 West Street New York NY 10282 154958 8941076.6 217641958 09/22/2025 NYSE Common 09/15/2025 Acquired as compensation - Restricted Stock Units Issuer N 11747 09/15/2025 Compensation Common 09/15/2025 A

144

144 0001894602 XXXXXXXX LIVE 0001773751 Hims & Hers Health, Inc. 001-38986 2269 CHESTNUT ST #523 SAN FRANCISCO CA 94123 415-851-0195 Becklund Irene Officer Class A Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 8410 424705.00 217641958 09/17/2025 NYSE Class A 09/15/2025 Restricted Stock Vesting Issuer N 8410 09/15/2025 Compensation N Irene Becklund 2269 Chestnut Street #523 S

144

144 0001837817 XXXXXXXX LIVE 0001773751 Hims & Hers Health, Inc. 001-38986 2269 CHESTNUT ST #523 SAN FRANCISCO CA 94123 415-851-0195 Boughton Soleil Officer Class A Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 2637 133168.50 217641958 09/17/2025 NYSE Class A 09/15/2025 Restricted Stock Vesting Issuer N 2637 09/15/2025 Compensation N Soleil Boughton 2269 Chestnut Street #523

144

144 0001837796 XXXXXXXX LIVE 0001773751 Hims & Hers Health, Inc. 001-38986 2269 CHESTNUT ST #523 SAN FRANCISCO CA 94123 415-851-0195 Dudum Andrew Officer Director Class A Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 65110 3292903.57 217641958 09/17/2025 NYSE Class A 09/15/2025 Restricted Stock Vesting Issuer N 65110 09/15/2025 Compensation N Andrew Dudum 2269 Chestnut Stree

144

144 0001965903 XXXXXXXX LIVE 0001773751 Hims & Hers Health, Inc. 001-38986 2269 CHESTNUT ST #523 SAN FRANCISCO CA 94123 415-851-0195 Chi Michael Officer Class A Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 13749 694324.50 217641958 09/17/2025 NYSE Class A 09/15/2025 Restricted Stock Vesting Issuer N 13749 09/15/2025 Compensation N Michael Y. Chi 2269 Chestnut Street #523 Sa

144

144 0001839736 XXXXXXXX LIVE 0001773751 Hims & Hers Health, Inc. 001-38986 2269 CHESTNUT ST #523 SAN FRANCISCO CA 94123 415-851-0195 Carroll Patrick Harrison Officer Director Class A Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 10021 506060.50 217641958 09/17/2025 NYSE Class A 09/15/2025 Restricted Stock Vesting Issuer N 10021 09/15/2025 Compensation N Patrick H. Carroll 22

144

144 0001837796 XXXXXXXX LIVE 0001773751 Hims & Hers Health, Inc. 001-38986 2269 CHESTNUT ST #523 SAN FRANCISCO CA 94123 415-851-0195 Dudum Andrew Officer Director Class A Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 175661 9384625.88 217641958 09/16/2025 NYSE Class A 03/15/2022 Restricted Stock Vesting Issuer N 13178 03/15/2022 Compensation Class A 03/15/2023 Restricted Sto

144

144 0001907056 XXXXXXXX LIVE 0001773751 Hims & Hers Health, Inc. 001-38986 2269 Chestnut Street Suite 523 San Francisco CA 94123 1-415-851-0195 Oluyemi Okupe Officer Common Goldman Sachs & Co. LLC 200 West Street New York NY 10282 145000 7824200 217641958 09/15/2025 NYSE Common 06/15/2024 Acquired as compensation - Restricted Stock Units Issuer N 9088 06/15/2024 Compensation Common 06/15/2024 Acqu

144

144 0001965903 XXXXXXXX LIVE 0001773751 Hims & Hers Health, Inc. 001-38986 2269 CHESTNUT ST #523 SAN FRANCISCO CA 94123 415-851-0195 Chi Michael Officer Class A Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917 4150 232400.00 217641958 09/15/2025 NYSE Class A 09/15/2025 Option Granted 08/10/2022 Issuer N 1800 09/15/2025 Cash Class A 09/15/2025 Option Granted 02/24/2022 Issuer N

[Signature on Following Page]

GUARANTY This Guaranty is made as of September 1, 2025 by HIMS & HERS HEALTH, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2025 HIMS & HERS HEA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

HIMS, INC., AS TENANT MENDEL NEW ALBANY PROPERTY OWNER LLC, AS LANDLORD 9885 INNOVATION CAMPUS WAY, NEW ALBANY, OHIO

LEASE BETWEEN HIMS, INC., AS TENANT AND MENDEL NEW ALBANY PROPERTY OWNER LLC, AS LANDLORD 9885 INNOVATION CAMPUS WAY, NEW ALBANY, OHIO The submission of an unsigned copy of this document to Tenant for Tenant’s consideration does not constitute an offer to lease the Premises or an option to or for the Premises. This document shall become effective and binding only upon the execution and delivery of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 HIMS & HERS HEALTH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

Amendment No. 1, dated as of June 25, 2025, by and among Hims & Hers Health, Inc. and JPMorgan Chase Bank, N.A., as administrative agent, to that certain Credit Agreement dated as of February 18, 2025.*

hims-20250630x10qxex103 Execution Version 1 AMENDMENT NO. 1 THIS AMENDMENT NO. 1 (this “Amendment”), dated as of June 25, 2025, by and among HIMS & HERS HEALTH, INC., a Delaware corporation (the “Borrower”), and JPMORGAN CHASE BANK, N.A. in its capacity as the Administrative Agent under the Existing Credit Agreement (as defined below), amends that certain Credit Agreement, dated as of February 18,

Feeling good in your body & mind transforms how you show up in life. That’s why we’re on a mission to help the world feel great through the power of better health. 2 Hims & Hers Q2 2025 Key Financial Highlights Q2 2025 Q2 2024 Growth Revenue $545M $3

finalq22025shareholderle Feeling good in your body & mind transforms how you show up in life.

Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results Revenue of $544.8 million, up 73% year-over-year in Q2 2025 Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025 Subscribers grew to over 2.4 million, up 31% y

Hims & Hers Health, Inc. Reports Second Quarter 2025 Financial Results Revenue of $544.8 million, up 73% year-over-year in Q2 2025 Net income of $42.5 million; Adjusted EBITDA of $82.2 million in Q2 2025 Subscribers grew to over 2.4 million, up 31% year-over-year in Q2 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and Adjusted EBITDA guidance of $295 million to $335

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO S

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 HIMS & HERS HEALTH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

Form of Confirmation of Base Call Option Transaction.

Exhibit 10.1 [Dealer Name and Address] May [], 2025 To: Hims & Hers Health, Inc. 2269 Chestnut Street #523 San Francisco, CA 94123 Attention: Legal Department Re: Base Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [Dealer Name] (“Dealer”) and Hims & Hers Health, Inc. (“Co

Form of Confirmation of Additional Call Option Transaction.

Exhibit 10.2 [Dealer Name and Address] May [ ], 2025       To: Hims & Hers Health, Inc. 2269 Chestnut Street #523 San Francisco, CA 94123 Attention: Legal Department Re: Additional Call Option Transaction The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [Dealer Name] (“Dealer”) and Hims & Hers Heal

Indenture, dated as of May 13, 2025, between Hims & Hers Health, Inc. and U.S. Bank Trust Company, National Association, as trustee.

Exhibit 4.1 EXECUTION VERSION HIMS & HERS HEALTH, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of May 13, 2025 0.00% Convertible Senior Notes due 2030 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1    Section 1.01. Definitions 1 Section 1.02. Other Definitions 13 Section 1.03. Rules of Construction 14 Article 2. The Notes 15 Section 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 HIMS & HERS HEALTH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 HIMS & HERS HEALTH, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission Fi

Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

Exhibit 99.2 Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare Proceeds intended to support Hims & Hers’ global expansion through organic growth and strategic acquisitions, while also fueling deeper investment in AI, diagnostics, and personalized treatments to scale access and meet rising dema

Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

EX-99.1 Exhibit 99.1 Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare • Proceeds intended to support Hims & Hers’ global expansion through organic growth and strategic acquisitions, while also fueling deeper investment in AI, diagnostics, and personalized treatments to scale access and meet rising deman

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 HIMS & HERS HEALTH, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission Fi

60orm iHSA100 milf595100 m Feeling good in your body & mind transforms how you show up in life. That’s why we’re on a mission to help the world feel great through the power of better health. 2 Hims & Hers Q1 2025 * This is a non-GAAP financial measur

60orm iHSA100 milf595100 m Feeling good in your body & mind transforms how you show up in life.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results Revenue of $586.0 million, up 111% year-over-year in Q1 2025 Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025 Subscribers grew to 2.4 million, up 38% year-o

Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results Revenue of $586.0 million, up 111% year-over-year in Q1 2025 Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025 Subscribers grew to 2.4 million, up 38% year-over-year in Q1 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and raises Adjusted EBITDA guidance to a range of $295 mil

Warehouse Lease Agreement by and between COI New Albany Industrial 300, LLC, and Hims, Inc.

Andrew Dudum CEO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

ARS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name of registrant as speci

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 HIMS & HERS HEALTH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

LETTER

April 17, 2025 Oluyemi Okupe Chief Financial Officer Hims & Hers Health, Inc. 2269 Chestnut Street, #523 San Francisco, California 94123 Re: Hims & Hers Health, Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 001-38986 Dear Oluyemi Okupe: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of t

Hims & Hers Health, Inc. | 2269 Chestnut Street, #523 | San Francisco, CA 94123

VIA EDGAR April 14, 2025 Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, D.

LETTER

March 31, 2025 Oluyemi Okupe Chief Financial Officer Hims & Hers Health, Inc. 2269 Chestnut Street, #523 San Francisco, California 94123 Re: Hims & Hers Health, Inc. Form 10-K for Fiscal Year Ended December 31, 2024 File No. 001-38986 Dear Oluyemi Okupe: We have reviewed your filing and have the following comments. Please respond to this letter within ten business days by providing the requested i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name of r

As filed with the Securities and Exchange Commission on February 24, 2025

As filed with the Securities and Exchange Commission on February 24, 2025 Registration No.

ent Contractor Advisor Agreement, dated November 15, 2024, by and between

INDEPENDENT CONTRACTOR ADVISOR AGREEMENT Effective as of the date the Board of Directors of Hims & Hers Health, Inc.

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results Revenue of $1.5 billion, up 69% year-over-year in 2024 Net income of $126 million; Adjusted EBITDA of $177 million in 2024 Subscribers grew to 2.2 million, up 45% ye

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results Revenue of $1.5 billion, up 69% year-over-year in 2024 Net income of $126 million; Adjusted EBITDA of $177 million in 2024 Subscribers grew to 2.2 million, up 45% year-over-year in 2024 Provides Q1 and full year 2025 guidance, with full year 2025 revenue in the range of $2.3 billion to $2.4 billion and Adjusted EB

Industrial Building Lease Agreement by and between LPC Mesa Gateway, LP and Hims, Inc., dated January 17, 2025 (incorporated by reference to Exhibit 10.12 to the Registrant’s Form 10-K for the period ended December 31, 2024 filed with the SEC on February 24, 2025).

SINGLE-TENANT INDUSTRIAL BUILDING LEASE Between LPC MESA GATEWAY, LP Landlord, and HIMS, INC.

List of Subsidiaries

Exhibit 21 SUBSIDIARIES OF HIMS & HERS HEALTH, INC. DOMESTIC COMPANIES Name Jurisdiction of Incorporation Hims, Inc. Delaware H&H Healthcare Management, Inc. Delaware H&H Pharmacy Management, Inc. Delaware H&H Pharmacy Holdings, Inc. Delaware H&H Peptides, Inc. Delaware H&H Labs, LLC Delaware Seaview Enterprises LLC California FOREIGN COMPANIES Name Jurisdiction of Incorporation Hims & Hers UK Lim

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 HIMS & HERS HEA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

Insider Trading Policy*

Hims & Hers Health, Inc. Insider Trading Policy Table of Contents Page Section I - Introduction 1 A. Legal Prohibitions on Insider Trading 1 B. Detection and Prosecution of Insider Trading 1 C. Penalties for Violation of Insider Trading Laws and This Policy 1 D. The Chief Legal Officer and the Chief Financial Officer Duties & Responsibilities 2 E. Reporting Violations 2 F. Personal Responsibility

iHSA100 milf595100 m Feeling good in your body & mind transforms how you show up in life. That’s why we’re on a mission to help the world feel great through the power of better health. 2 Hims & Hers Q4 2024 * This is a non-GAAP financial measure. Ple

iHSA100 milf595100 m Feeling good in your body & mind transforms how you show up in life.

eement, dated as of February 18, 2025, among Hims & Hers Health,

REVOLVING CREDIT AND GUARANTY AGREEMENT dated as of February 18, 2025, among HIMS & HERS HEALTH, INC.

Filing Fee Table

Calculation of Filing Fee Tables S-8 Hims & Hers Health, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Class A common Stock, par value $0.0001 per share Other 11,041,860 $ 53.21 $ 587,537,370.60 0.0001531 $ 89,9

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 HIMS & HERS HEA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

HIMS / Hims & Hers Health, Inc. / VANGUARD GROUP INC Passive Investment

SC 13G/A 1 UnitedStates13GHimsHersHe.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* (Name of Issuer) Hims & Hers Health Inc (Title of Class of Se

HIMS / Hims & Hers Health, Inc. / BlackRock, Inc. Passive Investment

SC 13G/A 1 us4330001060110724.txt us4330001060110724.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) Hims & Hers Health Inc - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 433000106 - (CUSIP Number) October 31, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appr

Hims & Hers Health, Inc. Reports Third Quarter 2024 Financial Results Revenue of $401.6 million, up 77% year-over-year in Q3 2024 Net income of $75.6 million; Adjusted EBITDA of $51.1 million in Q3 2024 Subscribers grew to 2.0 million, up 44% year-ov

Hims & Hers Health, Inc. Reports Third Quarter 2024 Financial Results Revenue of $401.6 million, up 77% year-over-year in Q3 2024 Net income of $75.6 million; Adjusted EBITDA of $51.1 million in Q3 2024 Subscribers grew to 2.0 million, up 44% year-over-year in Q3 2024 Raises full year 2024 revenue guidance to a range of $1.460 billion to $1.465 billion and Adjusted EBITDA guidance to a range of $1

HIMS / Hims & Hers Health, Inc. / VANGUARD GROUP INC Passive Investment

SC 13G/A 1 UnitedStates13GHimsHersHe.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* (Name of Issuer) Hims & Hers Health Inc (Title of Class of Se

HIMS / Hims & Hers Health, Inc. / VANGUARD GROUP INC Passive Investment

SC 13G/A 1 UnitedStates13GHimsHersHe.txt 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* (Name of Issuer) Hims & Hers Health Inc (Title of Class of Se

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact

100 milf595100 m Feeling good in your body & mind transforms how you show up in life. That’s why we’re on a mission to help the world feel great through the power of better health. 2 Hims & Hers Q3 2024 Key Financial Highlights Q3 2024 Q3 2023 Growth

100 milf595100 m Feeling good in your body & mind transforms how you show up in life.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commissi

LIMITED POWER OF ATTORNEY

EX-99.1 2 d898514dex991.htm EX-99.1 Exhibit 99.1 LIMITED POWER OF ATTORNEY Know all by these present, that I, Andrew Dudum, hereby make, constitute and appoint Soleil Boughton, Alexandra Cotter Wilkins and Kimberly Mather, acting individually, and with full power of substitution, as my true and lawful attorney-in-fact for the purpose of executing in my name, (a) in my personal capacity or (b) in m

HIMS / Hims & Hers Health, Inc. / Dudum Andrew - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 433000 106 (CUSIP Number) Andrew Dudum 2269 Chestnut Street, #523 San Francisco, California 94123 (415) 851-0195 (Name, Address an

HIMS / Hims & Hers Health, Inc. / BlackRock, Inc. Passive Investment

SC 13G/A 1 us4330001060102224.txt us4330001060102224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) Hims & Hers Health Inc - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 433000106 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the ap

Form of Indenture with respect to Debt Securities.

Exhibit 4.3 HIMS & HERS HEALTH, INC. and [ ], as Trustee Indenture Dated as of [ ] Debt Securities CROSS REFERENCE SHEET* Between Provisions of Trust Indenture Act (as defined herein) and Indenture, dated as of [], between HIMS & HERS HEALTH, INC. and [], as Trustee: SECTION OF THE ACT SECTION OF INDENTURE 310(a)(1) and (2) 6.9 310(a)(3) and (4) Inapplicable 310(b) 6.8 and 6.10(a), (b) and (d) 310

Filing Fee Table.

Calculation of Filing Fee Tables S-3 Hims & Hers Health, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective

As filed with the Securities and Exchange Commission on September 9, 2024

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 9, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 HIMS & HERS HEA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

976,341 shares of Class A Common Stock Offered by the Selling Stockholder

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(7)  Registration No. 333-282008 PROSPECTUS SUPPLEMENT (to Prospectus dated September 9, 2024) 976,341 shares of Class A Common Stock Offered by the Selling Stockholder This prospectus supplement relates to the potential offer and resale of up to 976,341 shares of Class A common stock (the “Resale Shares”) of Hims & Hers Health, Inc. (the “Company,”

Table 1: Newly Registered and Carry Forward Securities

Calculation of Filing Fee Tables S-3 Hims & Hers Health, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective

Hims & Hers Health, Inc. Reports Second Quarter 2024 Financial Results Revenue of $315.6 million, up 52% year-over-year in Q2 2024 Net income of $13.3 million; Adjusted EBITDA of $39.3 million in Q2 2024 Subscribers grew to 1.9 million, up 43% year-o

Hims & Hers Health, Inc. Reports Second Quarter 2024 Financial Results Revenue of $315.6 million, up 52% year-over-year in Q2 2024 Net income of $13.3 million; Adjusted EBITDA of $39.3 million in Q2 2024 Subscribers grew to 1.9 million, up 43% year-over-year in Q2 2024 Raises full year 2024 revenue guidance to a range of $1.37 billion to $1.40 billion and Adjusted EBITDA guidance to a range of $14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 HIMS & HERS HEALTH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

Feeling good in your body & mind transforms how you show up in life. That’s why we’re on a mission to help the world feel great through the power of better health. 2 Hims & Hers Q2 2024 Key Financial Highlights Q2 2024 Q2 2023 Growth Revenue $315.6M

finalq22024shareholderle Feeling good in your body & mind transforms how you show up in life.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 HIMS & HERS HEALTH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission F

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commissi

HIMS / Hims & Hers Health, Inc. / Institutional Venture Management XVI, LLC - SC 13D/A Activist Investment

SC 13D/A 1 tm2415368d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 433000 106 (CUSIP Number) Tracy Hogan Institutional Venture Partners 3000 Sand Hill Road Bu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 HIMS & HERS HEALTH, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission Fi

Hims & Hers Health, Inc. Reports First Quarter 2024 Financial Results Revenue of $278.2 million, up 46% year-over-year in 2024 Net income of $11.1 million; Adjusted EBITDA of $32.3 million in Q1 2024 Subscribers grew to 1.7 million, up 41% year-over-

Hims & Hers Health, Inc. Reports First Quarter 2024 Financial Results Revenue of $278.2 million, up 46% year-over-year in 2024 Net income of $11.1 million; Adjusted EBITDA of $32.3 million in Q1 2024 Subscribers grew to 1.7 million, up 41% year-over-year in Q1 2024 Raises full year 2024 guidance to a range of $1.20 billion to $1.23 billion and Adjusted EBITDA to a range of $120 million to $135 mil

Feeling good in your body & mind transforms how you show up in life. That’s why we’re on a mission to help the world feel great through the power of better health. 2 Hims & Hers Q1 2024 Key Financial Highlights Q1 2024 Q1 2023 Growth Revenue $278.2M

finalflatq12024sharehold Feeling good in your body & mind transforms how you show up in life.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ De

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2024 HIMS & HERS HEAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 HIMS & HERS HEALTH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

ARS

+$*
)**) )+(*)
$
.$
%##))%$ -2D9:?8E@?
 
  %(#
! 



((/&
,*),.
*/,-/(.
.)
-.#)(

),
;
)
."
-/,# .#-
2"(!
.
)
 @C
E96
:D42=
/62C
?565
646>36C
 
  ), 




.,(-#.#)(
,*),.
*/,-/(.
.)
-.#)(

),
;
)
."
- /,#.#-
2"(!
.
)

FI
K?<
KI8EJ@K@FE
G@JKI8EK
8J
JG<:@=@<;
@E
@KJ
:?8IKA=@J6C 56?E:7:42E:@?
$@  

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

HIMS / Hims & Hers Health, Inc. / Institutional Venture Management XVI, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name of r

Policy Relating to Recovery of Erroneously Awarded Compensation

Recovery of Erroneously Awarded Compensation Policy 1.Purpose. The purpose of this Policy is to describe the circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to members of the Company Group. This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Securities Exchange Act of 1934, as amen

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Hims & Hers Health, Inc.

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results Revenue of $872.0 million, up 65% year-over-year in 2023 Net income of $1.2 million; Adjusted EBITDA profitability of $20.6 million in Q4 2023 Subscribers grew to 1.

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results Revenue of $872.0 million, up 65% year-over-year in 2023 Net income of $1.2 million; Adjusted EBITDA profitability of $20.6 million in Q4 2023 Subscribers grew to 1.5 million, up 48% year-over-year in Q4 2023 Provides Q1 and full year 2024 guidance, with full year 2024 revenue in the range of $1.17 billion to $1.2

As filed with the Securities and Exchange Commission on February 26, 2024

As filed with the Securities and Exchange Commission on February 26, 2024 Registration No.

Shareholder Letter dated February 26, 2024

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

HIMS / Hims & Hers Health, Inc. / Abraham Jack Passive Investment

SC 13G/A 1 hims13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 3)* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 433000

HIMS / Hims & Hers Health, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01124-himshershealthinccla.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Hims & Hers Health, Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 433000106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropria

HIMS / Hims & Hers Health, Inc. / BlackRock Inc. Passive Investment

SC 13G 1 us4330001060013124.txt us4330001060013124.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) Hims & Hers Health Inc - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 433000106 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the approp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact

Hims & Hers Health, Inc. Reports Third Quarter 2023 Financial Results and Raises Full Year 2023 Outlook Revenue of $226.7 million, up 57% year-over-year in Q3 2023 Net loss of $7.6 million; Adjusted EBITDA profitability of $12.3 million in Q3 2023 Su

Hims & Hers Health, Inc. Reports Third Quarter 2023 Financial Results and Raises Full Year 2023 Outlook Revenue of $226.7 million, up 57% year-over-year in Q3 2023 Net loss of $7.6 million; Adjusted EBITDA profitability of $12.3 million in Q3 2023 Subscribers grew to 1.4 million, up 56% year-over-year in Q3 2023 Exited Q3 2023 with over 80% of orders fulfilled via affiliated facilities Raises full

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 HIMS & HERS HEAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

Hims & Hers Health, Inc. Reports Second Quarter 2023 Financial Results and Raises Full Year 2023 Outlook Revenue of $207.9 million, up 83% year-over-year in Q2 2023 Net loss of $7.2 million; Adjusted EBITDA profitability of $10.6 million in Q2 2023 S

Hims & Hers Health, Inc. Reports Second Quarter 2023 Financial Results and Raises Full Year 2023 Outlook Revenue of $207.9 million, up 83% year-over-year in Q2 2023 Net loss of $7.2 million; Adjusted EBITDA profitability of $10.6 million in Q2 2023 Subscribers grew to 1.3 million, up 74% year-over-year in Q2 2023 Raises full year 2023 revenue guidance to a range of $830 million to $850 million and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 HIMS & HERS HEALTH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 HIMS & HERS HEALTH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission F

HIMS / Hims & Hers Health Inc - Class A / NewView Capital Fund I, L.P. - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Securities) 433000106 (CUSIP Number) December 31, 2023

Hims & Hers Health, Inc. Reports First Quarter 2023 Financial Results and Raises Full Year 2023 Outlook Revenue of $190.8 million, up 88% year-over-year in Q1 2023 Net loss of $10.1 million; Adjusted EBITDA profitability of $6.1 million in Q1 2023 Su

Hims & Hers Health, Inc. Reports First Quarter 2023 Financial Results and Raises Full Year 2023 Outlook Revenue of $190.8 million, up 88% year-over-year in Q1 2023 Net loss of $10.1 million; Adjusted EBITDA profitability of $6.1 million in Q1 2023 Subscribers grew to over 1.2 million, up 87% year-over-year in Q1 2023 Raises full year 2023 revenue guidance to a range of $810 million to $830 million

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 HIMS & HERS HEALTH, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by Rul

FORM ARS

04182023Hims2022AnnualReportProduction.indd 1-3 4/18/23 12:34 PM04182023Hims2022AnnualReportProduction.indd 4-6 4/18/23 12:34 PM    
 FT4:ETT'AETL'T !E?4A'TF=T$'T!T1<&!:'LF3T !FTE%!7'T! <&T3!K'T I<4@I'7NT ?=E4F4=<'&TIETF=T 1AF3'AT4<<=K!F'T !<&T2=T !(F'AT!T2A>L4<2T !<&T 7!A2'7NT IEET:!A24<=AF3T=(T TL'T$'74'K'T!A'T!TF' EF!:'EET :!A6'FET F3'A'ET!T 2A=L4<2T'M?'%F!F4=&I%FE T!<&TE'

HIMS / Hims & Hers Health Inc - Class A / Redpoint Ventures VI, L.P. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.

HIMS / Hims & Hers Health Inc - Class A / Institutional Venture Management XVI, LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.

HIMS / Hims & Hers Health Inc - Class A / Forerunner Partners III, L.P. - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Hims & Hers Health, Inc.

As filed with the Securities and Exchange Commission on February 28, 2023

As filed with the Securities and Exchange Commission on February 28, 2023 Registration No.

Hims & Hers Health, Inc. 2020 Equity Incentive Plan and forms of agreement thereunder (incorporated by reference to Exhibit 10.

Hims & Hers Health, Inc. 2020 Equity Incentive Plan (As Adopted and approved by the Stockholders) Hims & Hers Health, Inc. 2020 Equity Incentive Plan ARTICLE 1. INTRODUCTION. The Board adopted the Plan to become effective immediately prior to the Closing (as defined in the Merger Agreement). The purpose of the Plan is to promote the long-term success of the Company and the creation of stockholder

Form of Change in Control and Severance Agreement

HIMS, INC. FORM OF CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control Severance Agreement (the “Agreement”) is made and entered into by and between [NAME OF EMPLOYEE OR DIRECTOR] (the “Executive”) and Hims, Inc., a Delaware corporation (the “Company”), effective as of the date specified in Section 1 below. This Agreement provides severance and acceleration benefits in connection with

Exhibit 4.2

Exhibit 4.2 DESCRIPTION OF THE COMPANY’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Authorized Capitalization The total amount of our authorized capital stock consists of 2,750,000,000 shares of Class A common stock, par value $0.0001 per share, 10,000,000 shares of Class V common stock, par value $0.0001 per share, and 275,000,000 shares of pre

Hims & Hers Health, Inc. Reports Record Fourth Quarter and Full Year 2022 Financial Results Full year 2022 revenue of $526.9 million, up 94% year-over-year Q4 2022 record revenue of $167.2 million, up 97% year-over-year Q4 2022 net loss of $10.9 mill

Hims & Hers Health, Inc. Reports Record Fourth Quarter and Full Year 2022 Financial Results Full year 2022 revenue of $526.9 million, up 94% year-over-year Q4 2022 record revenue of $167.2 million, up 97% year-over-year Q4 2022 net loss of $10.9 million and achieves Adjusted EBITDA profitability of $3.9 million Eclipses one million subscribers at year end, up 88% year-over-year Provides Q1 and ful

List of Subsidiaries*

Exhibit 21 SUBSIDIARIES OF HIMS & HERS HEALTH, INC. DOMESTIC COMPANIES Name Jurisdiction of Incorporation Hims, Inc. Delaware H&H Derm, LLC Delaware H&H Healthcare Management, Inc. Delaware H&H Pharmacy Management, Inc. Delaware FOREIGN COMPANIES Name Jurisdiction of Incorporation Hims & Hers UK Limited United Kingdom

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name of r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 HIMS & HERS HEA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2023 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 HIMS & HERS HEA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

HIMS / Hims & Hers Health, Inc. / NewView Capital Fund I, L.P. - SC 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, par value $0.0001 (Title of Class of Securities) 433000106 (CUSIP Number) December 31, 2022 (

HIMS / Hims & Hers Health, Inc. / Abraham Jack Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 2)* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 433000 106 (CUSIP Number) Decem

HIMS / Hims & Hers Health, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Hims & Hers Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 433000106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is file

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 HIMS & HERS HEAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commissi

Hims & Hers Health, Inc. Reports Third Quarter 2022 Financial Results and Raises Full Year 2022 Outlook; Platform Demand and Financial Outperformance Driving Expected Adjusted EBITDA Profitability Beginning in Q4 2022 Quarterly revenue of $144.8 mill

Hims & Hers Health, Inc. Reports Third Quarter 2022 Financial Results and Raises Full Year 2022 Outlook; Platform Demand and Financial Outperformance Driving Expected Adjusted EBITDA Profitability Beginning in Q4 2022 Quarterly revenue of $144.8 million in Q3 2022, up 95% year-over-year Consumer-centric strategy driving third straight quarterly gain of >100k net new subscriptions, ending Q3 2022 w

LETTER

United States securities and exchange commission logo October 14, 2022 Oluyemi Okupe Chief Financial Officer Hims & Hers Health, Inc.

Hims & Hers Health, Inc | 2269 Chestnut Street, #523 | San Francisco, CA 94123

VIA EDGAR October 11, 2022 Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, D.

LETTER

United States securities and exchange commission logo September 27, 2022 Oluyemi Okupe Chief Financial Officer Hims & Hers Health, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

Hims & Hers Health, Inc. Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Outlook Quarterly revenue of $113.6 million in Q2 2022, up 87% year-over-year Consumer-centric strategy driving second straight quarterly gain of >100k n

Hims & Hers Health, Inc. Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Outlook Quarterly revenue of $113.6 million in Q2 2022, up 87% year-over-year Consumer-centric strategy driving second straight quarterly gain of >100k net new subscriptions, ending Q2 2022 with 817,000 subscriptions, up 80% year-over-year Raises full year 2022 revenue guidance to the range of $470 mil

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission Fi

Hims & Hers Health, Inc. Reports First Quarter 2022 Financial Results and Raises Full Year 2022 Revenue Outlook Quarterly revenue surpassed the $100 million mark to $101.3 million in Q1 2022, up 94% year-over-year Largest-ever quarterly gain in membe

Hims & Hers Health, Inc. Reports First Quarter 2022 Financial Results and Raises Full Year 2022 Revenue Outlook Quarterly revenue surpassed the $100 million mark to $101.3 million in Q1 2022, up 94% year-over-year Largest-ever quarterly gain in member subscriptions, increasing 101,000 in the quarter, ending Q1 2022 with 710,000 subscriptions, up 82% year-over-year Raises full year 2022 revenue gui

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.??) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitte

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

Investor P

As filed with the Securities and Exchange Commission on March 9, 2022

As filed with the Securities and Exchange Commission on March 9, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Hims & Hers Health, Inc.

List of Subsidiaries*

Exhibit 21 SUBSIDIARIES OF HIMS & HERS HEALTH, INC. DOMESTIC COMPANIES Name Jurisdiction of Incorporation Hims, Inc. Delaware H&H Derm, LLC Delaware H&H Healthcare Management, Inc. Delaware H&H Pharmacy Management, Inc. Delaware FOREIGN COMPANIES Name Jurisdiction of Incorporation Hims UK Limited United Kingdom Honest Health Linited United Kingdom

Employment Agreement, dated as of December 21, 2021, by and between Hims, Inc. and Oluyemi Okupe (incorporated by reference to Exhibit 10.12 to the Registrant’s Form 10-K filed with the SEC on February 24, 2022).

Hims, Inc. 2269 Chestnut #523 San Francisco, CA 94123 December 20, 2021 Oluyemi Okupe Re: Offer Letter and Employment Terms Dear Yemi, 1.Position. HIMS INC. and/or any of its past, present, and future parent companies, subsidiaries, predecessors, successors, affiliates, and acquisitions (the ?Company?) is pleased to offer you the position of Chief Financial Officer, on the following terms. Per the

Description of registered securities*

Exhibit 4.2 DESCRIPTION OF THE COMPANY?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Authorized Capitalization The total amount of our authorized capital stock consists of 2,750,000,000 shares of Class A common stock, par value $0.0001 per share, 10,000,000 shares of Class V common stock, par value $0.0001 per share, and 275,000,000 shares of pre

Change in Control and Severance Agreement, dated as of January 24, 2022, by and between Hims, Inc. and Oluyemi Okupe.*

HIMS, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control Severance Agreement (the ?Agreement?) is made and entered into by and between Oluyemi Okupe (the ?Executive?) and Hims, Inc., a Delaware corporation (the ?Company?), effective as of the date specified in Section 1 below. This Agreement provides severance and acceleration benefits in connection with certain qualifying termi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTI

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name of r

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2022 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides First Quarter and Full Year 2022 Outlook Exceeded Q4 2021 and full year 2021 revenue and Adjusted EBITDA guidance Full year revenue grew 83% year-over-y

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides First Quarter and Full Year 2022 Outlook Exceeded Q4 2021 and full year 2021 revenue and Adjusted EBITDA guidance Full year revenue grew 83% year-over-year to $271.9 million. Q4 2021 revenue increased from Q3 2021 and grew 104% year-over-year to $84.7 million Q4 2021 ending member subscriptions grew 9

HIMS / Hims & Hers Health, Inc. / AMERIPRISE FINANCIAL INC - SC 13G/A Passive Investment

SC 13G/A 1 d315862dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Amendment #1 Under the Securities and Exchange Act of 1934 Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 433000106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

to Schedule 13G

Exhibit I to Schedule 13G Ameriprise Financial, Inc., a Delaware Corporation, is a parent holding company. The classification and identity of the relevant subsidiaries is as follows: Investment Adviser ? Columbia Management Investment Advisers, LLC is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.

to Schedule 13G Joint Filing Agreement

Exhibit II to Schedule 13G Joint Filing Agreement The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G dated February 14, 2022 in connection with their beneficial ownership of Hims & Hers Health, Inc.

HIMS / Hims & Hers Health, Inc. / Abraham Jack Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2. (Amendment No. 1)* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 433000 106 (CUSIP Number) Decem

HIMS / Hims & Hers Health, Inc. / Thrive Capital Partners V, L.P. - THRIVE CAPITAL PARTNERS V, L.P. / HIMS & HERS HEALTH -- SCHEDULE 13G/A(#1) Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) * Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 433000 106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to

HIMS / Hims & Hers Health, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Hims & Hers Health Inc. Title of Class of Securities: Common Stock CUSIP Number: 433000106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐

HIMS & HERS HEALTH, INC. 120,438,519 Shares of Class A Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS HIMS & HERS HEALTH, INC. 120,438,519 Shares of Class A Common Stock This prospectus relates to the offer and sale from time to time by the selling securityholders named in this prospectus (the ?Selling Securityholders?) of up to 120,438,519 shares of our Class A common stock, par value $0.0001 per share (?Cla

Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 4, 2022 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 005-91087 98-1482650 (State or other jurisdiction of incorporation) (Commissi

As filed with the Securities and Exchange Commission on February 4, 2022.

Table of Contents As filed with the Securities and Exchange Commission on February 4, 2022.

Hims, Inc. and Subsidiaries Consolidated Financial Statements Years Ended December 31, 2020 and 2019 Contents Report of Independent Registered Public Accounting Firm 1 Consolidated Financial Statements Consolidated Balance Sheets as of December 31, 2

Exhibit 99.1 C ONSOLIDATED F INANCIAL S TATEMENTS Hims, Inc. and Subsidiaries Years Ended December 31, 2020 and 2019 With Report of Independent Registered Public Accounting Firm Hims, Inc. and Subsidiaries Consolidated Financial Statements Years Ended December 31, 2020 and 2019 Contents Report of Independent Registered Public Accounting Firm 1 Consolidated Financial Statements Consolidated Balance

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2022 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commissi

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 8 (to Prospectus dated June 3, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated June 3, 2021 (the ?Prosp

HIMS / Hims & Hers Health, Inc. / Dudum Andrew - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hims & Hers Health, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value (Title of Class of Securities) 433000 106 (CUSIP Number) Andrew Dudum 2269 Chestnut Street, #523 San Francisco, California 94123 (415) 851-0195 (Name, Address an

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 7 (to Prospectus dated June 3, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated June 3, 2021 (the ?Prosp

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 6 (to Prospectus dated June 3, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated June 3, 2021 (the "Prosp

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 5 (to Prospectus dated June 3, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated June 3, 2021 (the "Prosp

Hims & Hers Health, Inc. Reports Third Quarter 2021 Financial Results Q3 2021 revenue grows 79% year-over-year to $74.2 million Q3 2021 ending member subscriptions grow 95% year-over-year to 551,000 Exceeds Q3 2021 revenue guidance, raises full year

Hims & Hers Health, Inc. Reports Third Quarter 2021 Financial Results Q3 2021 revenue grows 79% year-over-year to $74.2 million Q3 2021 ending member subscriptions grow 95% year-over-year to 551,000 Exceeds Q3 2021 revenue guidance, raises full year 2021 guidance SAN FRANCISCO, November 10, 2021 ? Hims & Hers Health, Inc. (?Hims & Hers?, NYSE: HIMS), a multi-specialty telehealth platform that conn

, 2021 announcing results for the quarter ended

Hims & Hers Health, Inc. Reports Third Quarter 2021 Financial Results Q3 2021 revenue grows 79% year-over-year to $74.2 million Q3 2021 ending member subscriptions grow 95% year-over-year to 551,000 Exceeds Q3 2021 revenue guidance, raises full year 2021 guidance SAN FRANCISCO, November 10, 2021 ? Hims & Hers Health, Inc. (?Hims & Hers?, NYSE: HIMS), a multi-specialty telehealth platform that conn

SPENCER LEE TO STEP DOWN AS HIMS & HERS HEALTH CHIEF FINANCIAL OFFICER Smooth six month transition plan in place; The search for Company’s next CFO has begun; Company reaffirms Q3 and FY 2021 guidance

Exhibit 99.1 SPENCER LEE TO STEP DOWN AS HIMS & HERS HEALTH CHIEF FINANCIAL OFFICER Smooth six month transition plan in place; The search for Company?s next CFO has begun; Company reaffirms Q3 and FY 2021 guidance SAN FRANCISCO (September 7, 2021) - Hims & Hers Health, Inc. (?Hims & Hers?, NYSE: HIMS), the multi-specialty telehealth platform that provides modern personalized health and wellness ex

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commissio

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 4 (to Prospectus dated June 3, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated June 3, 2021 (the ?Prosp

Warehouse Lease Agreement by and between COI New Albany Industrial 300, LLC, and Hims, Inc., dated January 27, 2020*†

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 3 (to Prospectus dated June 3, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated June 3, 2021 (the "Prosp

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated June 3, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated June 3, 2021 (the "Prosp

Hims & Hers Health, Inc. Incentive Bonus Plan*+

Hims & Hers Health, Inc. Incentive Bonus Plan ARTICLE 1.BACKGROUND AND PURPOSE 1.1Effective Date. This Plan became effective upon its adoption by the Committee and is not subject to approval by the Company?s stockholders. 1.2Purpose of the Plan. The Plan is intended to provide Participants with the possibility of earning incentive bonuses. ARTICLE 2.DEFINITIONS The following words and phrases shal

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commissio

Hims & Hers Health, Inc. Incentive Bonus Plan*+

Hims & Hers Health, Inc. Incentive Bonus Plan ARTICLE 1.BACKGROUND AND PURPOSE 1.1Effective Date. This Plan became effective upon its adoption by the Committee and is not subject to approval by the Company?s stockholders. 1.2Purpose of the Plan. The Plan is intended to provide Participants with the possibility of earning incentive bonuses. ARTICLE 2.DEFINITIONS The following words and phrases shal

Hims & Hers Health, Inc. Reports Second Quarter 2021 Financial Results Q2 2021 revenue grows 69% year-over-year to $60.7 million Q2 2021 online revenue grows 75% year-over-year to $58.1 million Exceeds Q2 2021 guidance, raises full year 2021 expectat

Hims & Hers Health, Inc. Reports Second Quarter 2021 Financial Results Q2 2021 revenue grows 69% year-over-year to $60.7 million Q2 2021 online revenue grows 75% year-over-year to $58.1 million Exceeds Q2 2021 guidance, raises full year 2021 expectations SAN FRANCISCO, August 11, 2021 ? Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), a multi-specialty telehealth platform that connects consum

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO S

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

, 2021 announcing results for the quarter ended

Hims & Hers Health, Inc. Reports Second Quarter 2021 Financial Results Q2 2021 revenue grows 69% year-over-year to $60.7 million Q2 2021 online revenue grows 75% year-over-year to $58.1 million Exceeds Q2 2021 guidance, raises full year 2021 expectations SAN FRANCISCO, August 11, 2021 ? Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), a multi-specialty telehealth platform that connects consum

Warehouse Lease Agreement by and between COI New Albany Industrial 300, LLC, and Hims, Inc., dated January 27, 2020*†

EX-99.25

NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on August 20, 2021, pursuant to the provisions of Rule 12d2-2 (a).

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated June 3, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated June 3, 2021 (the ?Prosp

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission F

NOTICE OF REDEMPTION OF ALL OUTSTANDING WARRANTS (CUSIP 433000114)

Exhibit 99.2 July 9, 2021 NOTICE OF REDEMPTION OF ALL OUTSTANDING WARRANTS (CUSIP 433000114) Dear Warrant Holder, Hims & Hers Health, Inc. (the ?Company?) hereby gives notice that it is redeeming, at 5:00 p.m. New York City time on August 9, 2021 (the ?Redemption Date?), all of the Company?s outstanding warrants (the ?Warrants?) to purchase shares of the Company?s Class A common stock, par value $

Hims & Hers Announces Redemption of All Outstanding Warrants

Exhibit 99.1 Hims & Hers Announces Redemption of All Outstanding Warrants SAN FRANCISCO?(BUSINESS WIRE)? Hims & Hers Health, Inc. (?Hims & Hers? or the ?Company,? NYSE: HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, today announced that it will redeem all of its outstanding warrants (the ?Warrants?) to purchase

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus relates to the offer and sale from time to time by the selling securityholders named in this prospectu

As filed with the Securities and Exchange Commission on June 2, 2021.

Table of Contents As filed with the Securities and Exchange Commission on June 2, 2021.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.?? ) Filed by the Registrant ? Filed by a Party other than the Registrant ?? Check the appropriate box: ?? ? ? Preliminary Proxy Statement ?? ? ? Confidential, for Use of the Commission Only (as permitt

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name

Hims & Hers Health, Inc. Reports First Quarter 2021 Financial Results Q1 2021 revenue grows 74% year-over-year to $52.3 million Q1 2021 gross margin of 77% compared to 69% in Q1 2020 Exceeds Q1 2021 guidance, raises full year 2021 revenue expectation

Hims & Hers Health, Inc. Reports First Quarter 2021 Financial Results Q1 2021 revenue grows 74% year-over-year to $52.3 million Q1 2021 gross margin of 77% compared to 69% in Q1 2020 Exceeds Q1 2021 guidance, raises full year 2021 revenue expectations SAN FRANCISCO, May 17, 2021 ? Hims & Hers Health, Inc. (?Hims & Hers?, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 1 (to Prospectus dated March 23, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated March 23, 2021 (the ?P

HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants

Filed Pursuant to Rule 424(b)(3) Registration No. 333-252814 PROSPECTUS SUPPLEMENT NO. 2 (to Prospectus dated March 23, 2021) HIMS & HERS HEALTH, INC. 174,516,077 Shares of Class A Common Stock 3,904,086 Warrants to Purchase Shares of Class A Common Stock 10,612,401 Shares of Class A Common Stock Underlying Warrants This prospectus supplement supplements the prospectus dated March 23, 2021 (the ?P

Regulation FD Disclosure, Financial Statements and Exhibits, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2021 HIMS & HERS HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38986 98-1482650 (State or other jurisdiction of incorporation) (Commission Fi

Hims & Hers Health, Inc. Announces Response to Recent SEC Guidance Applicable to Warrants Issued by Special Purpose Acquisition Companies (“SPACs”)

Exhibit 99.1 Hims & Hers Health, Inc. Announces Response to Recent SEC Guidance Applicable to Warrants Issued by Special Purpose Acquisition Companies (?SPACs?) SAN FRANCISCO - (BUSINESS WIRE) - Hims & Hers Health, Inc. (?Hims & Hers?, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, today announced that, as a result of guidance provi

Annual Report - 10-K/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to HIMS & HERS HEALTH, INC. (Exact name of regi